Atrophic Age-related Macular Degeneration (AMD) Treated With Intravitreal Injections of Umbilical Cord Blood Platelet-rich Plasma (CB-PRP): a Pilot Study (CORD-IV)
Dry Age-related Macular Degeneration
About this trial
This is an interventional treatment trial for Dry Age-related Macular Degeneration
Eligibility Criteria
Inclusion Criteria: Age ≥65 years Bilateral dry-AMD ETDRS-corrected visual acuity between (or equal to) 1/10 and 4/10 No concomitant ocular pathology (e.g., Glaucoma, amblyopia) or systemic pathology that would result in a BIAS for primary goal assessment Signature of informed consent Exclusion Criteria: Age < 65 years Pregnancy Previous inflammatory/infectious events involving the eyes Eye trauma, diabetes, or disease potentially damaging to the visual system, even in the absence of impairment at the time of intake Previous intravitreal treatments. Refusal to sign informed consent.
Sites / Locations
- Fondazione Policlinico Universitario Agostino Gemelli IRCCSRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Monthly injection
Bimonthly injection
Quarterly injection
The patients will recive 12 intravitreal injections in one eye and 12 sham injections in the other eye each month
The patients will receive 6 intravitreal injections in one eye and 6 sham injections in the other eye each two months
The patients will receive 4 intravitreal injections in one eye and 4 sham injections in the other eye each three months